War against cancer: a fine wave tuning may deliver the right death signal

A new targeted therapy using non-thermal radio waves has been shown to block the growth of liver cancer cells anywhere in the body without damaging healthy cells, according to a study conducted by scientists at Wake Forest School of Medicine, part of Wake Forest Baptist Health. The study findings are published on the journal EBioMedicine, a Lancet publication. Using animal models, the research team headed by Boris Pasche, MD, PhD, chair of cancer biology and director of the Comprehensive Cancer Center at Wake Forest Baptist, delivered levels of radio frequencies to mice that had been injected with human cancer cells to replicate hepatocellular carcinoma (HCC), the most common type of liver cancer. The radio frequencies were the same as those delivered to patients with HCC in Europe where the device has been approved for use in people. The research team utilized a device, invented by Pasche and Alexandre Barbault, of TheraBionic GmbH in Ettlingen, Germany, that delivered cancer-specific, amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) programmed specifically for HCC.

Pasche and Barbault have discovered radio frequencies for 15 different types of cancer, as previously reported in a study published in 2009 in the Journal of Experimental & Clinical Cancer Research. A separate study the researchers using the same technology with breast cancer cells has also been published in the May 31 edition of EBioMedicine. The device, which is licensed to TheraBionic Inc., formerly TheraBionic LLC, and TheraBionic GmbH, has been approved by the European Notified Body, the equivalent of the U.S. Food and Drug Administration (FDA). It is currently under review by the FDA. Pasche and Barbault hold stock in TheraBionic Inc. and TheraBionic GmbH. The treatment, which is approved for use in patients in Europe, consists of a hand-held device about the size of a VHS tape cassette that emits radio frequencies via a spoon-shaped element that is placed on the patient’s tongue. The treatment is administered at the patient’s home three times a day for one hour. The frequencies used are specific to the patient’s type of cancer as identified through tumor biopsies or blood work.

The AM RF EMF activated a calcium channel on the surface of HCC tumor cells but not on normal cells. The study showed that the radiofrequency delivered was at low and safe levels. It was actually lower than those generated by holding a cell phone close to the ear. Preliminary experiments confirmed that a specific calcium channel, Cav3.2 (CACNA1H), was acting like an antenna for the radio signals emitted by the device, which allowed calcium to enter inside hepatoma cells, triggering HCC growth arrest. An odd result, since calcium influx are usually involved in promoting cell proliferation. On the other hand, sustained calcium influx may cause cellular toxicity, a phenomenon that is commonly seen in brain cells. Indeed, the influx of calcium that stopped the growth of HCC cells and shrunk, and in some cases eliminated, the tumors. This effect was the same even if the cancer had metastasized to other parts of the body. The team’s next step will be to identify the exact signaling cascade within the tumor cell that leads to the anti-cancer effects.

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Jimenez H et al., Pasche BC. EBioMedicine 2019 May 24. 

Sharma S et al., Watabe K. EBioMedicine  2019 May 22. 

Hughes RT et al., Chan MD. Neurosurgery. 2018 Jul 6.

Jimenez H et al., Pasche B. Front Biosci. 2018; 23:284-97. 

Zimmerman JW et al. Br J Cancer. 2012; 106:307–313.

Informazioni su Dott. Gianfrancesco Cormaci 1569 Articoli
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry specialty in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Detentore di un brevetto sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento immunologicamente neutralizzata (owner of a patent concerning the production of bakery gluten-free products, starting from regular wheat flour). - Autore di un libro riguardante la salute e l'alimentazione, con approfondimenti su come questa condizioni tutti i sistemi corporei. - Autore di articoli su informazione medica, salute e benessere sui siti web salutesicilia.com e medicomunicare.it

Commenta per primo